New catheter targets pancreatic cancer tumors directly
NCT ID NCT07575191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new catheter system that delivers the chemotherapy drug Gemcitabine directly into or near pancreatic tumors. It includes 9 patients with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach is safe and feasible, with patients receiving four treatments over eight weeks and followed for six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karolinska University Hospital
RECRUITINGSolna, 171 64, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New device aims to make pancreatic and bile duct procedures safer
- New personalized vaccine takes on tough cancers
- Radiation boost may help control advanced pancreatic cancer
- New radiation bead treatment targets Hard-to-Treat pancreatic tumors
- New study compares two drainage techniques to ease jaundice in advanced cancer patients